Dc. Miskulin et al., Comorbidity assessment using the Index of Coexistent Diseases in a multicenter clinical trial, KIDNEY INT, 60(4), 2001, pp. 1498-1510
Background. The Hemodialysis (HEMO) Study is a multicenter trial designed t
o determine whether hemodialysis dose and membrane flux affect survival. Co
morbid conditions are also important determinants of survival, and thus, an
accurate and reliable method to assess comorbidity was required. Comorbidi
ty was being assessed at baseline and annually in the HEMO Study using the
Index of Coexistent Disease (ICED). We describe the instrument. its impleme
ntation in the HEMO Study, and the results of comorbidity assessment in the
first 1000 randomized patients in the trial.
Methods. The ICED aggregated the presence and severity of 19 medical condit
ions and 11 physical impairments within two scales: the Index of Disease Se
verity (IDS) and the Index of Physical Impairment (IPI). The final ICED sco
re was determined by an algorithm combining the peak scores for the IDS and
IPI. The range of the ICED was from 0 to 3, reflecting increasing severity
.
Results. Study personnel at 15 clinical centers were trained to update and
abstract data from the dialysis medical records. Availability of data, meas
ures of construct validity, and measures of reliability were adequate; 99.8
% and 60.6% of patients had comorbid conditions in at least one IDS or IPI
category, respectively. The distribution of patients by ICED level was 0 (0
2%), 1 (34.9%). 2 (31.2%), and 3 (33.7%). In multivariable analysis, the fo
llowing factors were significantly associated with more severe comorbidity:
older age, diabetes and other causes of renal disease, a lower level of ed
ucation, employment status (unemployed and retired), longer duration of dia
lysis, and lower serum creatinine. There was a significant variation in the
severity of comorbidity among clinical centers after adjustment for other
factors. The R-2 of the model was 25.3%, indicating that a substantial prop
ortion of the variation in the ICED was not explained by these factors.
Conclusions. We conclude that comorbidity assessment using the ICED is feas
ible in multicenter clinical trials of dialysis patients. There is a large
burden of comorbidity in dialysis patients, which is not well explained by
the cause of renal disease, demographic, and socioeconomic factors and comm
on clinical and laboratory measurements. These variables should not be cons
idered substitutes for comorbid conditions in case-mix adjustment. Comorbid
ity assessment is useful to describe the sample population, to improve the
precision of the treatment effect, and to use possibly as an outcome measur
ement.